Innovative Medicine: nipocalimab in gMG; RYBREVANT Sub-Q in NSCLC; TREMFYA Sub-Q in UC; TAR-200 NMIBC; icotrokinra in PsO and UC; RYBREVANT in ...

Dr Nicholas Silvestri reports that the 2025 AAN meeting highlighted significant advances in myasthenia gravis, including improved diagnostics and emerging therapies.

Johnson & Johnson’s Q1 2025 earnings reveal growth in sales and EPS, boosted by MedTech and Pharma. Click for my updated look at JNJ and its most recent news.

Good morning, and welcome to Johnson & Johnson's First Quarter 2025 Earnings Conference Call. All participants will be in listen-only mode until the question-and-answer session of the conference. This ...